360biolabs to join R&D efforts to combat coronavirus disease
2 March 2020
360biolabs today announced it is excited to offer assays to support COVID-19 vaccine development and enable laboratory testing of new antivirals and biologics.
On January 29th, 2020 Melbourne’s Peter Doherty Institute for Infection and Immunity became the world’s first scientific laboratory outside China to successfully grow SARS-2-CoV, the causative agent of the COVID-19 outbreak. Following this major breakthrough in the global fight against coronavirus, 360biolabs moved quickly to secure access to the virus.
360biolabs is Australia’s first commercially focused ISO accredited laboratory to offer virology and immunology testing for COVID-19 vaccine development. Our quality systems drive our preclinical and clinical activities from custom research to full assay validation, compliant with ICH, FDA and EMA regulatory standards.
360biolabs hopes to accelerate efforts to control COVID-19. “We have been approached by a number of global biotechnology and pharmaceutical companies seeking a specialty lab with extensive virology and immunology expertise to assess their potential antiviral compounds or support a vaccine trial.” said Angela Luttick, Executive VP, Business Development. “We are excited to be able to offer this capability in our secure Physical Containment 3 (PC3) facility and are passionate about playing our part in finding a cure and/or vaccine for this debilitating outbreak” added Melinda Pryor, Executive VP, Clinical at 360biolabs.
The team at 360biolabs is driven by quality with internationally recognised accreditation. The expert virologists at 360biolabs are well known in industry for their antiviral drug discovery and development experience at Biota Pharmaceuticals. The current Executive team led antiviral discovery efforts at Biota for 15 years before launching 360biolabs in partnership with the Burnet Institute in 2015.